NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs NGR-TNF (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors MolMed
- 08 Oct 2015 Planned End Date changed from 1 Dec 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 17 Jun 2013 Status changed from active, no longer recruiting to completed.
- 04 Jun 2013 Final results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History